Castle Biosciences (CSTL) Operating Expenses (2018 - 2026)

Castle Biosciences has reported Operating Expenses for 9 years, with the latest figure at $106.6 million in Q2 2026.

• Quarterly Operating Expenses rose 17.89% year-over-year to $106.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $389.4 million (up 5.43% YoY) and the FY2025 annual result came in at $387.0 million, up 19.68% from the prior year.
• Operating Expenses rose to $106.6 million in Q2 2026 per CSTL's latest filing, from $102.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $115.9 million in Q1 2025 and troughed at $38.8 million in Q2 2022.
• A 5-year average of $78.7 million and a median of $79.6 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses surged 89.57% in 2022, then dropped 11.93% in 2026.
• Over 5 years, Operating Expenses stood at $61.2 million in 2022, then grew by 17.34% to $71.8 million in 2023, then increased by 14.6% to $82.3 million in 2024, then grew by 10.43% to $90.8 million in 2025, then climbed by 17.37% to $106.6 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $106.6 million, $102.1 million, and $90.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.